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ABSTRACT 
Proteases are enzymes that catalyze the hydrolysis of specific peptide bonds in proteins, a 
process referred to as proteolysis. Proteases are largely responsible for processes such as 
apoptosis, immune response, protein turnover, digestion, blood coagulation and wound healing, 
fertilization, cell differentiation and growth, and cell signaling among other processes. Thus, 
uncontrolled proteolysis can lead to many disease states, such as cancer, neurological disorders, 
viral infections, inflammation, and arthritis.  Aza-peptide aldehydes and ketones are a new class 
of inhibitors designed to inhibit the proteasome and the clan CD cysteine proteases for the 
potential treatment of cancer and neurodegenerative disorders. These compounds are designed 
starting with the structure of a good target protease substrate structure. The α-carbon of the P1 
amino acid residue is replaced with a nitrogen atom to make an Aza-amino acid residue and the 
scissile peptide bond is replaced with an aldehyde or ketone moiety. Aza-peptides are more rigid 
than their peptide analogs due to the inability of the N-CO bond at the P1 site to rotate. We 
hypothesize that the rigidity of aza-peptides makes these inhibitors more selective, as other 
proteases will be unable to accommodate this rigidity while the proteasome and the clan CD 
cysteine proteases will be able to. Here I will present the synthesis and the kinetic inhibition 
study of the first examples of the proteasome and the clan CD cysteine protease specific aza-
peptide aldehyde and ketone inhibitors.	
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1. INTRODUCTION 
 
Proteases are enzymes that catalyze the hydrolysis of specific peptide bonds in proteins, a 
process referred to as proteolysis (Figure 1.1) 1. To date approximately six hundred proteases 
have been identified, which make up ~2% of the genomes 2. Proteases play an important role in 
cell processes such as apoptosis, immune response, protein turnover, digestion, blood 
coagulation and wound healing, fertilization, cell differentiation and growth, and cell signaling 
among other processes 3. Due to their large involvement in such processes, uncontrolled 
proteolysis can lead to many disease states such as cancer, neurological disorders, viral 
infections, inflammation, and arthritis 3. Uncontrolled proteolysis can be stopped by inhibition, 
thus research in design and synthesis of novel inhibitors is of interest to many researchers today 
4.  While many inhibitors have been synthesized, most are nonselective and react with other 
proteases. Thus they cannot be considered as therapeutic agents. Hence, the challenge in protease 
inhibition is to come up with a design, where the electrophilic warhead is reactive enough to 
result in inhibition, and inert enough to be specific for the targeted protease family or clan. 
Proteases are categorized into families based on lineage: cysteine, serine, threonine, aspartic and 
metallo proteases. Clan definition is based mainly on 3-D structure/fold of the proteases within 
the same family. Proteases have been found to adapt to a variety of conditions, such as pH and 
reductive environments to name a couple 1. 
 
 Figure 1.1. Proteolysis of peptide bonds in proteins 
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Successful inhibition of proteases has been achieved with both reversible inhibitors (Figure 1.2) 
and irreversible inhibitors (Figure 1.3). A successful inhibitor is comprised of an ideal peptide 
chain that is recognized by its target protease that is attached to an electrophilic group for 
inhibition.  
 
 Figure 1.2. Reversible inhibitors of cysteine serine, and threonine proteases 
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 Figure 1.3. Irreversible inhibitors of cysteine, serine and threonine proteases 
 
One specific target, the 20S proteasome will be further explored here. Proteasome is a 
threonine protease, which degrades proteins by the ubiquitin proteasome pathway (UPP) 1, 5. 
Uncontrolled proteolysis is observed in cancers such as Multiple Melanoma (MM) and Non-
Hodgkin’s Lymphoma (NHL) 6, 7. Inhibition of proteasome leads to death of cancerous cells 8, 9. 
Proteasomes involvement in MM and NHL make it an interest to investigators in the field. 
Currently three proteasome inhibitors are on the market, however, due to unwanted side effects 
such as peripheral neuropathy, fatigue, generalized weakness, nausea, diarrhea, vomiting and 
poor appetite, infective results and drug resistance, new inhibitors are still needed (Figure 1.4) 10, 
11, 12.  
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Figure 1.4. Proteasome inhibitors approved by the Food and Drug Administration (FDA) 
for treatment of MM 
 
The proteasome complex is comprised of the 20S proteasome core, which consist of two inner β 
subunits and two outer α subunits, with two 19S regulatory caps at either end, which regulate 
entry of proteins into the active sites (Figure 1.5). There are three active sites within the 
proteasome: chymotrypsin-like, trypsin-like and caspase-like 13.  
 
  
Figure 1.5. Proteasome complex image 12 
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Clan CD cysteine proteases, specifically caspase-3 and legumain inhibitors, will also be 
further explored here. Clan CD cysteine proteases are distinctive to other classes of proteases, 
because of their unique α/β fold; furthermore this clan shows high specificity at the P1 site 14.  
Cysteine proteases have been discovered in bacteria, protozoa, fungi, plant viruses and mammals 
15. Hydrolysis by clan CD cysteine proteases involves catalytic attack of a nucleophilic thiol in 
the active site. 
Caspases are a part of a family of more than 15 members, 11 of these members have been 
identified in humans 16. Members of this family have been identified as playing key roles in 
inflammation and apoptosis 17. Caspase-3 is involved in neuronal apoptosis; uncontrolled 
apoptosis can cause neurological disorders such as Alzheimer’s disease, spinal muscular atrophy, 
Parkinson’s disease, Huntington’s disease, Amyotropic Lateral Sclerosis (ALS) and Multiple 
Sclerosis (MS) 18. Caspase’s involvement in these diseases has made it a target of interest, 
however, there are currently no caspase inhibitors in the drug market available for the treatment 
of such diseases.  
The second clan CD cysteine protease of interest is legumain. To date legumain has been 
identified in mammals, parasites and plants. Legumain has been identified as an important 
component of the life cycle of a parasite called S. mansoni, which can be found in infected 
humans 19. Contracting this parasite can be detrimental to human life; thus treatment is required. 
While treatments for this parasite are available, there are concerns about drug resistance exist. 
Thus researchers are compelled to discover new drugs 20. Research has shown that inhibition of 
key proteases in mice affected by the parasite had a decrease in parasite activity, thus inhibition 
of legumain is a promising target 20. Similar to caspase-3, there are currently no legumain 
inhibitors available in the drug market for such treatments.  
	 6	
Nomenclature 
The aza-amino acid group at the P1 site will be referred to as “A” followed by the 
abbreviated amino acid name. Figure 1.6 will be referred to for site specificity for proteasome, 
caspase-3 and legumain as well as the design of our inhibitor.  
 
Figure 1.6. Protease nomenclature by Schechter and Berger 21 
Inhibitor Design 
Aza-peptide aldehydes’ and ketones’ design starts with the structure of a good target 
protease substrate. The α-carbon of the P1 amino acid residue is replaced with a nitrogen atom to 
make an aza-amino acid residue and the scissile peptide bond is replaced with an aldehyde or 
ketone moiety (Figure. 1.7). Aza-peptides are more rigid than their peptide analogs due to the 
inability of the N-CO bond at the P1 site to rotate. Aza-peptide inhibitor design for proteasome, 
caspase and legumain is shown below in Figure 1.7.  
 
 Figure 1.7. Aza-peptide aldehyde and ketone inhibitor design 
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We hypothesize that the rigidity of aza- peptides makes these inhibitors more selective, as other 
proteases will be unable to accommodate this rigidity while the proteasome and the clan CD 
cysteine proteases will be able to. Past research on caspase and legumain inhibitors has shown 
that this clan of cysteine protease tolerates aza-peptides 15, 22.      
 We expect our compounds to be reversible covalent inhibitors. Reversible covalent 
inhibitors are believed to be less toxic than their counterparts, because they often do not reach 
sufficient levels to induce an immune response, making them desirable drug candidates 23.   
2. Results and Discussion 
 
2.1 Synthesis 
Peptides 2 were synthesized by general peptide coupling procedure where a protected amino acid 
was coupled to either an amino methyl ester or peptidyl methyl ester by reacting with iBCF and 
NMM in THF overnight at rt. Peptidyl hydrazides were synthesized by reacting methyl ester 
with hydrazine in methanol overnight at rt 3. Hydrogenation to deprotect peptides was done by 
reacting a protected peptide with hydrogen, palladium on carbon in methanol at rt overnight. 
Substituted peptidyl hydrazides were synthesized by reductive amination of peptidyl hydrazide 
with sodium cyanoborohydride, catalytic amounts of acetic acid and an aldehyde in methanol 
overnight at rt. Substitution of carbonyl chloride by substituted peptidyl hydrazide gave aza-
peptide ketones’ and aldehydes’ 5.  Aza-peptide ketones and aldehydes were synthesized by 
reacting oxyl chloride with carboxyl acid derivatives and catalytic amounts of DMF in DCM 
under argon at rt for 2.5 h then concentrated. Concentrated product was reacted with substituted 
peptidyl hydrazides and DIPEA under argon in DCM overnight at rt.  The majority of the final 
compounds were synthesized and characterized by Thomas Corrigan. 
	 8	
 
 
 Scheme 2.1. General reactions of aza-peptide aldehyde and ketone inhibitors 
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2.2   Proteasome Inhibitors.  
PG	 P3	 P2	 P1	 Warhead	 Ki	(μM)	
	Z	 Leu	 Leu	 ALeu	 COMe	 27.39	±	7.0	
	Z	 Leu	 Leu	 ALeu	 COBn	 81.10	±	15.8	
	Z	 Leu	 Leu	 ALeu	 COH	 23.84	±	8.1	
	Z	 Leu	 Phe	 ALeu	 COMe	 46.67	±	19.5	
	Z	 Leu	 Phe	 ALeu	 COBn	 54.78	±	13.7	
	Z	 Leu	 Phe	 ALeu	 COH	 Not	tested	
	Z	 Leu	 Leu	 AGly	 COMe	 29.36	±	6.9	
	Z	 Leu	 Leu	 AGly	 COH	 34.88	±5.2	
	Z	 Leu	 Leu	 AAla	 COMe	 73.23	±	13.6	
	Z	 Leu	 Leu	 AAla	 COH	 44.01	±	8.1	
	Pz	 -	 Phe	 ALeu	 COMe	 474	±	343	
	Pz	 -	 Phe	 ALeu	 COBn	 Not	tested	
	aZ	 Leu	 Leu	 Leu	 COH	 0.0142	±	0.003	
	a: the commercial inhibitor MG132 
Table 2.1. Inhibition of the 20S proteasome by aza-peptide aldehyde and ketone 
inhibitors 
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Table 2.2 Synthesized aza-peptide 20S proteasome inhibitors 
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 Aza-peptide aldehyde and ketone compounds are found to be potent inhibitors of 
proteasome. Molecular docking of α-ketohydrazide in the β5 subunit showed a distance of 2.94 
Å between the electrophilic warhead and oxygen of the catalytic threonine, which supports the 
hypothesized mechanism of action, nucleophilic attach of the warhead by –O-Thr. Our inhibitor 
design is based on specificity of the chymotrypsin-like active site. Chymotrypsin-like active site 
prefers tripeptides that are non-charged and hydrophobic 24. A variety of aza-peptides and 
warheads were synthesized, then tested against the 20S proteasome; a commercially sold 
inhibitor (MG 132) was also tested for comparison. The inhibitor constant for the synthesized 
inhibitors is listed in Table 2.1. Our aza-peptide aldehyde and ketone inhibitors have Ki values in 
the lower micro M range. Our most potent inhibitor is Z-Leu-Leu-ALeu- COH. For all of the 
inhibitors the methyl ketone and aldehyde warhead, were more potent than the benzyl ketone. 
This could be explained by the bulkiness of the benzyl group, making nucleophilic attack more 
difficult. The aldehyde outperformed the methyl ketone for two of the three tested sequences. 
Analysis of the aza-peptide sequence Z-Leu-Leu-AAla-COR showed a decrease in potency for 
all of the warheads attached to it, thus it can be concluded that at the P1 site AAla is not as 
favored over ALeu or AGly at P1. Replacement of Leu at the P2 position with Phe showed a 
decrease in potency for the methyl ketone, however, potency for benzyl ketone increased. 
Replacement of ALeu at the P1 position with AGly resulted in the methyl ketone being more 
potent than the aldehyde. Our least potent inhibitor was Pz-Phe-ALeu-COBn that was 
synthesized in part as a comparison to bortezomib (Figure 1.4). The decrease in strength of this 
inhibitor is not entirely unexpected given the active site’s preference for tripeptides. Our specific 
inhibitors were tested for cross reactivity with the clan CA cysteine protease cathepsin B. Kinetic 
results showed no inhibition of cathepsin B. 
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2.3   Caspase-3 Inhibitors 	
PG	 P4	 P3	 P2	 P1	 Warhead	 IC50	(μM)	
	Z	 Asp	 Glu	 Val	 AAsp	 COH	 Not	tested	
	Z	 Asp	 Glu	 Val	 AAsp	 COMe	 Not	tested	
	Z	 Asp	 Glu	 Leu	 AAsp	 COBn	 Not	tested	
	Z	 Asp	 Glu	 Leu	 Asp	 COH	 Not	tested	 		
	 	 	 	 	 	 	 	Table 2.3. Synthesized aza-peptides aldehyde and ketones specific for caspase-3  
 
 
Table 2.4. Synthesized caspase-3 aza-peptide aldehyde and ketone inhibitors 
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however, not tested against caspase-3 at this time. Caspase 3 has a preference for tetra peptides 
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preferred (Figure 1.6) 25. Our inhibitor design is based on this preference. Kinetic studies of Z-
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and no inhibition of papain. This is somewhat surprising because proteasome prefers 
hydrophobic peptides and the inhibitor tested against it possesses two hydrophilic groups.  
Additionally, papain is less specific in preference than proteasome, only having a preference that 
at the P2 site the residue be hydrophobic and bulky, however, unlike proteasome there was no 
inhibition observed. 
2.4   Legumain Inhibitors 
 
PG	 P3	 P2	 P1	 Warhead	 IC50	(μM)	
Z	 Ala	 Ala	 AAsn	 COMe	 Weak	
Z	 Ala	 Ala	 AAsn	 COOEt	 Weak	
Z	 Ala	 Ala	 AAsn	 COBn	 Weak	
  
Table 2.5. Inhibition of legumain by aza-peptide aldehyde and ketone inhibitors  
 
 
Table 2.6. Synthesized aza-peptide ketone’s legumain inhibitors 
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Kinetic studies of our inhibitors tested against legumain resulted in weak inhibition 
(Table 2.5). Our design was based on peptide specificity of schistosome legumain, the P1 site 
shows a preference for Asn likewise the P2 has a preference for Ala and P3 has a preference for 
Thr followed by Ala 26.  Previous inhibition studies with aza-peptide epoxides show potent 
inhibition of legumain, therefore weak inhibition cannot be attributed to the rigidity of the aza-
peptide 27. Weak inhibition must therefore be a result due to the difference in the electrophilic 
warhead and not the aza-peptide that it is attached to.  
 
3. Current and Future Work 
3.1 Proteasome. Current work is focused on synthesizing tetrapeptide analogs of Carfilzomib 
(Figure 1.4) where at the P1 site Leu is replaced with ALeu, at the P2 site Phe is replaced with 
Leu and the protecting group Z at the N-terminal is replaced with morpholine, these 
modifications are expected to increase potency. A variety of warheads including the ones 
presented here will be attached to that peptide sequence. In the future, we plan to test our 
inhibitors in vivo with cancer cell lines with collaborators at OSU Medical Center. 
3.2 Caspase.  Future work is focused on synthesizing and testing aza-peptide ketone and 
aldehyde inhibitors for clan CD cysteine proteases caspase -6 and -8.  
 
 
4. Experimental 
4.1 Methods. All reagents were purchased from Sigma Aldrich, Oakwood Chemical, Bachem or 
ApexBio and used without further purification. Dry THF was obtained from the solvent system 
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in the department of chemistry and used for all peptide couplings. Compounds were purified by 
column chromatography as necessary. Final products were verified by 1H NMR and ESI.  
Procedure was written and performed by Thomas Corrigan a chemistry graduate student, 
and Dr. Özlem Doğan Ekici at The Ohio State University. Proteasome kinetic assay details: 
Human 20S proteasome, 700 kDa was purchased from Boston Biochem (50 µg, 2 µM (1.4 
mg/mL)) in 50 mM HEPES buffer pH 7.6, 100 mM NaCl, 1 mM DTT. Assay buffer was 
prepared as follows: 20 mM HEPES buffer pH 7.8, 0.5 mM EDTA, 0.037% SDS. Proteasome 
specific substrate Suc-LLVY-AMC was purchased from Boston Biochem and used as 
fluorogenic substrate; λex = 380 nm, λem = 442 nm. Assay Protocol: 18 µL of 2 µM proteasome 
solution was diluted with 425 µL H2O to make 0.06 µM stock enzyme solution for kinetic 
assays. In a 96-well plate suitable for fluorometric assay was added 86 µL assay buffer, 2 µL 
inhibitor, 2 µL enzyme substrate, and 10 µL of 0.06 µM enzyme stock solution (0.06 nM enzyme 
concentration in well). Fluorescence at 442 nM was monitored for 10 min. The enzyme activity 
was measured at varying concentrations of inhibitor (0, 25, 50, 100 µM in DMSO) and substrate 
(10, 20, 50, 100 µM in DMSO) by converting the slope of the plot of fluorescence intensity at 
442 nm vs time for time points between 4 and 8 min using Lambert-Beer’s law. Ki values were 
obtained from non-linear fitting of the data to a competitive inhibition model using GraphPad 
Prism 4.0 software. 
Legumain kinetic assay details. Activation: same-pichia powder- was diluted in water. 
IrAE solution in water. 3 h at rt; activation in activation buffer: 0.1 M Na-Ac pH 4.0;5 mM DTT. 
Assay buffer: 0.1 M Na-Ac pH 5.5; 2.5 mM DTT; 0.1 % PEG 6000. Substrate: Z-AAN-AMC; 
50 µM final in assay. Inhibitors in DMSO; (1 % DMSO in activity assay) incubation period 10 
min at rt. 
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4.2 Procedures of Synthesized Compounds. 
Z-Leu-Leu-OMe. Z-Leu-OH (1 eq) was dissolved in dry THF and cooled to -20 °C. NMM (1 
eq) and iBCF (1 eq) were added dropwise and the mixture was allowed to react for 30 min. H-
Leu-OMe (1 eq) was dissolved in dry THF and cooled to -20 °C. NMM (1 eq) were added 
dropwise and the mixture was allowed to react for 15 min. The two mixtures above were added 
together. The combined mixture was stirred for 1 h at -20 °C and was allowed to react for 18 h at 
room temperature. The solvent was evaporated and the residue was treated with EtOAc and H2O. 
The organic layer was washed with 1 M HCl, H2O, salted NaHCO3, and salted NaCl, dried over 
Na2SO4, filtered and concentrated to give Z-Leu-Leu-OMe as a white in 90% yield. 1H NMR 
(DMSO-d6): 1.18 (m, 12 H, (CH3)2CH),  1.47 (m, 2 H, (CH3)2CH), 1.56 (m, 4 H, 
(CH3)2CHCH2),  3.59 (s, 3 H, OCH3), 4.03 (m, 1 H, NCHCH2C), 4.27 (t, 1 H, NCHCH2C), 5.00 
(s, 2 H, CH2Ph), 7.35 (m, 5 H, Ph), 8.19 (d, 1 H, NH).  
Z-Ala-Ala-OMe. See procedure and workup of Z-Leu-Leu-OMe. A white solid in 83% yield 
was obtained. 1H NMR (DMSO-d6): 1.21 (d, 3 H, CH3CH), 1.29 (d, 3 H, CH3CH), 3.62 (s, 3 H, 
CH3O), 4.08 (t, 1 H, CH3CH), 4.27 (t, 1 H, CH3CH), 5.01 (s, 2 H, CH2Ph) 7.36 (m, 5 H, Ph), 
8.26 (d, 1 H, NH). 
Z-Leu-Phe-OMe. See procedure and workup of Z-Leu-Leu-OMe. A white solid in 83% yield 
was obtained. 1H NMR (DMSO-d6): 0.86 (q, 6 H, (CH3)2CHCH2), 1.37 (m, 2 H, (CH3)2CHCH2), 
1.57 (m, (CH3)2CHCH2), 2.98 (m, 2 H, CHCH2Ph), 3.59 (s, 3 H, OCH3), 4.06 (m, 1 H, NHCH), 
4.47 (q, 1 H, NHCH), 5.02 (s, 2 H, PhCH2O), 7.17-7.39 (m, 10 H, Ph), 8.28, (d, 1 H, NH). m, 5 
H, Ph), 7.60 (d, 1 H, NH), 7.92 (d, 1 H, NH), 8.12 (d, 1 H, NH).  
Z-Asp(OtBu)-Glu(OtBu)-Val-OMe. See procedure and workup of Z-Leu-Leu-OMe. A White 
foam in 86% yield was obtained. 1H NMR (DMSO-d6): 0.88 (t, 6 H, (CH3)2CH), 1.37 (s, 9 H, 
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(CH3)3O), 1.40 (s, 9 H, (CH3)3O), 1.77 (m, 1 H, CH2CH2), 1.88 (m, 1 H, CH2CH2), 2.05 (q, 1 H, 
(CH3)2CH), 2.22 (t, 2 H, CH2CH2), 2.43 (dd, 1 H, CHCH2CO), 2.50 (dd, 1 H, CHCH2CO), 3.62 
(s, 3 H, CH3O), 4.00-4.19 (m, 2 H, NHCH), 4.37 (m, 1 H, NHCH), 5.04 (d, 2 H, CH2Ph), 7.35 
(m, 5 H, Ph), 7.60 (d, 1 H, NH), 7.92 (d, 1 H, NH),  8.12 (d, 1 H, NH).  
Z-Glu(otBu)-Val-OMe. See procedure and workup of Z-Leu-Leu-OMe. Product obtained as a 
clear oil. 1H NMR (DMSO-d6): 0.88 (t, 6 H, (CH3)2CH), 1.39 (s, 9 H, (CH3)3O), 1.72 (m, 1 H, 
CH2CH2), 1.85 (m, 1 H, CH2CH2), 2.05 (q, 1 H, (CH3)2CH), 2.25 (t, 2 H, CH2CH2), 3.63 (s, 3 H, 
CH3O), 4.16 (m, 2 H, NHCH), 5.02 (d, 2 H, CH2Ph), 7.35 (m, 5 H, Ph), 7.42 (d, 1 H, NH), 8.10 
(d, 1 H, NH). 
Pz-Phe-OMe. Pyrazinecarboxylic acid (1 eq) was dissolved in DCM and cooled to -20 °C 
followed by the addition of EDC (1.5 eq), HOBt (1 eq), H-Phe-OMe (1 eq) and DIPEA (1.2 eq 
dropwise), the solution was warmed to rt and allowed to react for 18 h. The solvent was 
evaporated and the residue was treated with EtOAc and H2O. The organic layer was washed with 
salted NaHCO3, citric acid (10%), salted NaHCO3, H2O and salted NaCl, dried over Na2SO4, 
filtered and concentrated to give Pz-Phe-OMe as a yellow oil in 95% yield. 1H NMR (DMSO-
d6): 3.23 (d, 2 H, CH2Ph), 3.67 (s, 3 H, OCH3), 4.82 (t, 1 H, NCH), 7.24 (s, 5 H, Ph), 8.75 (d, 1 
H, CHNCCO), 8.89 (d, 1 H, CHCHNC), 9.08 (d, 1 H, CONH), 9.13 (s, 1 H, NCHCCO). 
Pz-Phe-NHNH2. Pz-Phe-OMe (1eq) was dissolved in methanol followed by the addition of 
hydrazine (10 eq), the solution was allowed to react for 18 h at rt. The solvent was evaporated to 
obtain Pz-Phe-NHNH2 as yellow oil in 100% yield. 1H NMR (DMSO-d6): 3.07 (d, 2 H, 
CHCH2Ph), 4.29 (s, 2H, NH2), 5.48 (m, 1 H, NCH), 7.22 (t, 5 H, Ph), 8.69 (d, 1 H, CHNCCO), 
8.74 (d, 1 H, CHCHNC), 8.87 (d, 1 H, CONHCH), 9.10 (s, 1 H, NHNH2), 9.37 (s, 1 H, 
NCHCCO). 
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Z-Ala-Ala-NHNH2. Follow procedure of Pz-Phe-NHNH2. Z-Ala-Ala-NHNH2 was obtained as a 
white solid in 100% yield. 1H NMR (DMSO-d6): 1.19 (d, 6 H, CHCH3), 4.07 (m, 2 H, NH2), 
4.24 (m, 2 H, CHCH3), 5.03 (s, 2 H, PhCH2), 7.33 (s, 5 H, Ph), 7.43 (d, 1 H, NHCH), 7.91 (d, 1 
H, NHCH), 9.06 (s, 1 H, NHNH2).  
Z-Leu-Leu-NHNH2. Follow procedure of Pz-Phe-NHNH2. Z-Leu-Leu-NHNH2 was obtained as 
white solid in 100% yield. 1H NMR (DMSO-d6): 0.82-0.88 (m, 12 H, CH2CH(CH3)2), 1.38 (m, 4 
H, CH2CH(CH3)2), 1.55 (m, 2 H, CH(CH3)2), 4.06 (m, 1 H, NCHCH2), 4.27 (m, 1 H, NCHCH2), 
5.03 (s, 2 H, PhCH2), 7.39 (m, 5 H, Ph), 7.44 (d, 1 H, NHCH), 7.86 (d, 1 H, NHCH), 9.18 (s, 1 
H, NHNH2). 
Pz-Phe-NHN=CHCH(CH3)2. Pz-Phe-NHNH2 (1 eq) was dissolved in dry THF followed by the 
addition of isobutyraldehyde (1.1 eq), sodium triacetoyborohydride (1.27 eq) and catalytic 
amounts of AcOH (dropwise). The solution was allowed to stir for 18 h at rt. The reaction was 
quenched with sodium bicarbonate then extracted with DCM and concentrated to obtain Pz-Phe-
NHN=CHCH(CH3)2 as a yellow oil in 94% yield. 1H NMR (DMSO-d6): 1.04 (d, 3 H, 
CH(CH3)2), 1.10 (d, 3 H, CH(CH3)2), 3.14 (m, 2 H, CH2Ph), 5.43 (m, 1 H, NCH), 7.25 (s, 5 H, 
Ph), 7.38 (d, 1 H, NHCH), 7.45 (d, 1 H, NCHCH(CH3)2), 8.76 (d, 1 H, NCH), 8.89 (d, 1 H, 
CHNCH), 9.12 (d, 1 H, NCHCCO), 11.22 (s, 1 H, NNH). 
Z-Leu-Leu-NHN=CHCH(CH3)2. Follow procedure for Pz-Phe-NHN=CHCH(CH3)2. Z-Leu-
Leu-NHN=CHCH(CH3)2 was concentrated to obtain a white solid in 100% yield. 1H NMR 
(DMSO-d6): 0.84 (d, 18 H, CH(CH3)2), 0.99 (t, 4 H, CH2CH(CH3)2), 0.99 (t, 1 H, CH(CH3)2), 
1.39 (t, 2 H, CH(CH3)2),  4.03 (m, 2 H, NHCH), 5.02 (s, 2 H, PhCH2), 7.37 (m, 5 H, Ph), 7.41 (d, 
1 H, NH), 7.74 (d, 1 H, NH), 7.93 (d, 1 H, NH), 10.81,11.01 (s, 1 H, N=CHCH(CH3)2).  
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Pz-Phe-NHNH-CHCH(CH3)2. Pz-Phe-NHN=CHCH(CH3)2 (1 eq) was dissolved in methanol 
and cooled in an ice bath followed by the addition of sodium borohydride (3 eq) and allowed to 
react for 36 h at rt. Product was quenched with 1 M HCl and extracted with DCM and H2O, then 
concentrated and purified by column using methanol in DCM as the eluent to obtain Pz-Phe-
NHNH-CHCH(CH3)2 as a yellow solid in 45% yield. 1H NMR (DMSO-d6): 0.84 (d, 3 H, 
CHCH2(CH3)2), 0.85 (d, 3 H, CHCH2(CH3)2), 2.44 (t, 2 H, CHCH2(CH3)2), 3.09 (t, 2 H, CH2Ph), 
5.44 (m, 1 H, NCH), 7.24 (m, 5 H, Ph), 7.38 (d, 1 H, NH), 7.45 (d, 1 H, NH), 8.76 (d, 1 H, 
CHNC), 8.90 (d, 1 H,CHNCH), 9.13 (d, 1 H, NCHCHCO), 11.22 (s, 1 H, N=CH). 
Pz-Phe-ALeu-COMe. Pyruvic acid (3.4 eq) and oxalyl chloride (3.4 eq) were reacted in DCM 
with catalytic amounts of DMF under argon at rt for 2.5 h. 2-oxopropanoyl chloride (3.4 eq) was 
concentrated then dissolved in DCM and cooled in an ice bath followed by the addition of Pz-
Phe-NHNH-CHCH(CH3)2 (1 eq) and DIPEA ( 3.4 eq) the solution was brought to rt and was 
allowed to react for 18 h under argon. Product was extracted with DCM, H2O and salted NaCl 
dried with sodium sulfate then purified by column using methanol and DCM as the eluent to 
obtain Pz-Phe-ALeu-COMe as a brown solid in 15% yield. 1H NMR (CD2Cl2): 0.78 (d, 6 H, 
CH2CH(CH3)2), 2.14 (s, 3 H, CH3), 3.09 (q, 1 H, CH2Ph), 3.16 (m, 2 H, NCH2), 3.24 (q, 1 H, 
CH2Ph), 4.71 (q, 1 H, NHCH), 7.20 (m, 5 H, Ph), 8.06 (d, 1 H, CHNCCO), 8.35 (d, 1 H, 
CHNCH), 8.47 (d, 1 H, NH), 8.73 (s, 1 H, NCHCCO), 9.30 (s, 1 H, NHN). 
Pz-Phe-ALeu-COBn. Follow procedure for Pz-Phe-Aleu-COMe. To obtain Pz-Phe-ALeu-
COBn as a brown solid in 1.8% yield. 1H NMR (CD2Cl2): 0.82 (d, 6 H, CH2CH(CH3)2), 3.11 (q, 
1 H, CH2Ph), 3.19 (m, 2 H, CH2CH(CH3)2), 3.38 (q, 1 H, CH2Ph), 4.00 (d, 2 H, COCH2Ph), 4.70 
(q, 1 H, HNCH), 7.21-7.35 (m, 10 H, Ph), 7.99 (d, 1 H, CHNCCO), 8.32 (d, 1 H, CHNCH), 8.52 
(d, 1 H, NHCHCH2), 8.79 (s, 1 H, NCHCCO), 9.33 (s, 1 H, NHN). 
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ESI: 
Pz-Phe-ALeu-COBn: (C27H29N5NaO4) Measured 510.2114 m/z, Theoretical  
510.2112 m/z  
Pz-Phe-ALeu-COMe: (C21H25N5NaO4) Measured 434.1810 m/z, Theoretical  
434.1810 m/z  
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Z-Leu-Phe-OMe 
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Z-Ala-Ala-OMe 
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Pz-Phe-OMe 
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Z-Glu(OtBu)-Val-OMe 
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Z-Asp(OtBu)-Glu(OtBu)-Val-OMe 
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Z-Leu-Leu-NHNH2 
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Z-Ala-Ala-NHNH2 
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Pz-Phe-NH-NH2 
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